HDAC9 and prostate adenocarcinoma: While much of the tumor growth inhibitory properties of fimepinostat appeared attributable to HDAC inhibition, we also demonstrate that there is additivity or synergy associated with combining HDAC and PI3K inhibitors in prostate adenocarcinoma and NEPC, demonstrating the importance of dual HDAC/PI3K targeting.